Important Note Click to maximise
Important Note I have read and agree, click to minimise

This is a financial promotion for The First Sentier China Strategy. This information is for professional clients only in the UK and EEA and elsewhere where lawful. Investing involves certain risks including:

  • The value of investments and any income from them may go down as well as up and are not guaranteed. Investors may get back significantly less than the original amount invested.
  • Currency risk: the Fund invests in assets which are denominated in other currencies; changes in exchange rates will affect the value of the Fund and could create losses. Currency control decisions made by governments could affect the value of the Fund's investments and could cause the Fund to defer or suspend redemptions of its shares.
  • Single country / specific region risk: investing in a single country or specific region may be riskier than investing in a number of different countries or regions. Investing in a larger number of countries or regions helps spread risk.
  • China market Risk: although China has seen rapid economic and structural development, investing there may still involve increased risks of political and governmental intervention, potentially limitations on the allocation of the Fund's capital, and legal, regulatory, economic and other risks including greater liquidity risk, restrictions on investment or transfer of assets, failed/delayed settlement and difficulties valuing securities..
  • Concentration risk: the Fund invests in a relatively small number of companies which may be riskier than a fund that invests in a large number of companies.
  • Smaller companies risk: Investments in smaller companies may be riskier and more difficult to buy and sell than investments in larger companies.

For details of the firms issuing this information and any funds referred to, please see Terms and Conditions and Important Information.  

For a full description of the terms of investment and the risks please see the Prospectus and Key Investor Information Document for each Fund. 

If you are in any doubt as to the suitability of our funds for your investment needs, please seek investment advice.

china-hero.jpg

China

Navigate Greater China’s evolving landscape with a different perspective.

China as the second largest economy in the world with Hong Kong and Taiwan as key regional markets offers interesting growth opportunities. 

house.svg

Dominant consumer franchises

We believe dominant consumer franchises and brands should benefit from rising incomes and the premiumisation trend, and can offer good growth potential over the long term.

medical.svg

Rise in healthcare spending

China’s per capita spend on healthcare is still relatively low and has room to grow. We believe that companies providing drugs and medical services should benefit from an increased focus on healthcare spending and wellbeing.

chart.svg

High quality financials

We believe banks and high quality financials should benefit from similar drivers as consumer businesses: demographics, rising incomes and urbanisation.

connect.svg

A more connected and automated world

We believe an increased focus on research and development should lead to technology champions in niche markets. Domestic component manufacturers could benefit from the trend towards localised production.
 

About the strategy

China is evolving, with the market developing and broadening out driven by increasing innovation; it is no longer just about state-owned companies. 

Martin Lau, Managing Partner explains the key investment themes for the Greater China investment strategy.

China

Our investment philosophy

FSSA Investment Managers’ investment approach is centred on identifying quality companies, buying them at a sensible price and holding for the long term.

We look for founders and management teams that act with integrity and risk awareness; and dominant franchises that have the ability to deliver sustainable and predictable returns over the long term.

We are research-driven, bottom-up investors1, carrying out detailed fundamental analysis2 to identify high quality companies to invest in for the long term. We travel extensively to meet with companies to assess the quality of management and their track record of executing long-term strategies; and supplement this with a qualitative and quantitative analysis of the company’s ability to compound growth in excess of the cost of capital.

1. Bottom-up investing is an investment approach that focuses on the analysis of individual stocks and de-emphasizes the significance of macroeconomic cycles.
2. Fundamental analysis is a method of measuring a security's intrinsic value by examining related economic and financial factors.

Our approach to sustainability

Environmental, social and governance (ESG) analysis is fully integrated into our investment process. 

Our approach to responsible investing has been shaped by an emphasis on stewardship and the belief that quality managers and good governance should ensure that environmental and social concerns are rightfully addressed.

To us, sustainability is not just a label, but a set of values by which we operate.

As a firm, we have been signatories to the Principles of Responsible Investment (PRI) since 2007 (we view it as a minimum standard) and are constantly striving to better understand how ESG and sustainability issues impact long-term investment performance.

pharmaceutical.png

Case study: Corporate governance

CSPC Pharmaceutical is one of the largest drug companies in China. In 2007, a private equity buy-out effectively turned the company into a private enterprise with an ownership structure that aligns management and shareholders .

FSSA Investment Managers has been a long-term shareholder of CSPC and, over time, we have engaged with management on a variety of issues such as broader distribution of compensation and attracting talent.

We also highlighted the benefits of having someone with multinational corporation (MNC) experience on the board; subsequently the company appointed Mr Chen Chuan, an ex-VP of Johnson & Johnson China, as a director. Our engagement with the company highlighted that management is open-minded and willing to listen, which we see as a positive.

 

Disclaimer: Reference to specific securities (if any) is included for the purpose of illustration only and should not be construed as a recommendation to buy or sell the same. All securities mentioned herein may or may not form part of the holdings of FSSA Investment Managers' portfolios at a certain point in time, and the holdings may change over time.

Investment Insights

Meet the managers

Martin-Lau.jpg

Martin Lau

Managing Partner

Helen-Chen.jpg

Helen Chen

Portfolio Manager

Winston-Ke.jpg

Winston Ke

Portfolio Manager

For more information, please contact us